ArticleACS omega2020

Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy.

Mudasir Nabi Peerzada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.